公开(公告)号：US20250064788A1

公开(公告)日：2025-02-27

申请号：US18945079

申请日：2024-11-12

Applicant: Allergan Pharmaceuticals International Limited ,  Merck Sharp & Dohme LLC

Inventor： Joel M. Trugman ,  Ramesh Boinpally ,  Abhijeet Jakate ,  Michelle Finnegan ,  Mary Ann Johnson ,  Leonardo R. Allain ,  W. Mark Eickhoff ,  Craig B. Ikeda ,  Chad D. Brown ,  Francis J. Flanagan ,  Rebecca Nofsinger ,  Melanie Marota ,  Lisa Lupton ,  Paresh B. Patel ,  Hanmi Xi ,  Wei Xu

IPC: A61K31/4375 ,  A61K31/4545 ,  A61P25/06

Abstract: The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.

公开(公告)号：US20250059174A1

公开(公告)日：2025-02-20

申请号：US18797882

申请日：2024-08-08

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Jiajun ZHANG ,  Yuk Ming SIU ,  Peilin XU ,  Matthew C. RHODES ,  Hui CAO ,  Yat Sun OR ,  Xuri GAO ,  Wei LI ,  Xuechao XING ,  Scott MITCHELL

IPC: C07D413/14 ,  A61K31/4245 ,  A61K31/429 ,  A61K31/433 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/497 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/541 ,  A61K31/553 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D495/04 ,  C07D498/04 ,  C07D513/04 ,  C07D519/00

Abstract: The invention provides compounds of formulae (I), or pharmaceutically acceptable salts and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors; as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit, CSF1R, and PDGFR (PDGFRα, PDGFRβ) kinases.

公开(公告)号：US20250057863A1

公开(公告)日：2025-02-20

申请号：US18940508

申请日：2024-11-07

Applicant: Insmed Incorporated

Inventor： Gina EAGLE ,  Renu GUPTA

IPC: A61K31/7036 ,  A61K9/00 ,  A61K9/127 ,  A61K31/133 ,  A61K31/407 ,  A61K31/4375 ,  A61K31/4409 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/5383 ,  A61K31/546 ,  A61K31/65 ,  A61K31/7048 ,  A61K31/7052 ,  A61K45/06 ,  A61P31/04

Abstract: Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and/or NTM culture conversion to negative during or after the administration period.

公开(公告)号：US20250057822A1

公开(公告)日：2025-02-20

申请号：US18720410

申请日：2022-12-19

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  SALK INSTITUTE FOR BIOLOGICAL STUDIES

Inventor： David E. OLSON ,  Uri MANOR

IPC: A61K31/4375 ,  A61K31/4045 ,  A61P27/16

Abstract: Provided herein are psychoplastogens which can be useful for treating hearing loss.

公开(公告)号：US12213968B2

公开(公告)日：2025-02-04

申请号：US18795731

申请日：2024-08-06

Applicant: Deciphera Pharmaceuticals, LLC

Inventor： Michael D. Kaufman ,  Scott Bone ,  Corey Bloom ,  Fred Jordan

IPC: A61K31/4375 ,  A61K9/00 ,  A61K9/10 ,  A61K47/38

Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFRα kinases, and oncogenic forms thereof.

公开(公告)号：US20250034128A1

公开(公告)日：2025-01-30

申请号：US18894069

申请日：2024-09-24

Applicant: BeiGene, Ltd.

Inventor： Ling Qin ,  Yunhang Guo ,  Zhiwei Wang

IPC: C07D417/14 ,  A61K31/429 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5383 ,  C07D471/04 ,  C07D487/04 ,  C07D498/04 ,  C07D513/04 ,  C07D519/00

Abstract: Disclosed herein is a compound of Formula (I) for inhibiting Bcl-xL and treating a disease associated with the undesirable Bcl-xL activity (Bcl-xL related diseases), a method of using the compounds disclosed herein for treating tumor or cancer, and a pharmaceutical composition comprising the same.

公开(公告)号：US20250032466A1

公开(公告)日：2025-01-30

申请号：US18913072

申请日：2024-10-11

Applicant: Allergan Pharmaceuticals International Limited

Inventor： Ramesh Boinpally ,  Joel Trugman

IPC: A61K31/4375 ,  A61K31/496 ,  A61K45/06 ,  A61P25/06

Abstract: The present disclosure provides methods for the treatment of migraine by the administration of atogepant or a pharmaceutically acceptable salt thereof.

公开(公告)号：US12209089B1

公开(公告)日：2025-01-28

申请号：US18631374

申请日：2024-04-10

Applicant: KING FAISAL UNIVERSITY

Inventor： Michelyne Haroun ,  Christophe Tratrat

IPC: C07D471/22 ,  A61K31/4375

Abstract: Novel pyrimido[1′,6′: 1,5]pyrazolo[4,3-c][2,7]naphthyridine compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrimido[1′,6′: 1,5]pyrazolo[4,3-c][2,7]naphthyridine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.

公开(公告)号：US12208099B2

公开(公告)日：2025-01-28

申请号：US17275178

申请日：2019-09-09

Applicant: Mirati Therapeutics, Inc.

Inventor： Ruth Wei Aranda ,  James Gail Christensen ,  Lars Daniel Engstrom ,  Jill Hallin ,  Peter Olson

IPC: A61K31/519 ,  A61K31/428 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5377 ,  A61K45/06 ,  A61P35/00

Abstract: The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a Raf family kinase inhibitor and a KRAS G12C inhibitor of Formula (I), Formula (I-A) or Formula (I-B), pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.

公开(公告)号：US20250017947A1

公开(公告)日：2025-01-16

申请号：US18739657

申请日：2024-06-11

Applicant: Novartis AG

Inventor： Mark J. Cornfeld ,  Rakesh Kumar ,  Shannon Renae Morris

IPC: A61K31/58 ,  A61K31/4155 ,  A61K31/4375 ,  A61K45/06

Abstract: A novel combination comprising a 17 α-hydroxylase/C17,20 lyase inhibitor, for example: (3β)-17-(pyridin-3-yl)androsta-5,18-dien-3-ol or a pharmaceutically acceptable salt or ester thereof, and an AKT inhibitor, for example: N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, and optional additional antineoplastic agents; pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of 17 α-hydroxylase/C17,20 lyase and/or AKT inhibition is beneficial, e.g., cancer.